| Drug Name |
Lifitegrast |
| Drug ID |
BADD_D01290 |
| Description |
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805]. |
| Indications and Usage |
For the treatment of signs and symptoms of keratoconjunctivitis sicca (dry eye syndrome). |
| Marketing Status |
approved |
| ATC Code |
S01XA25 |
| DrugBank ID |
DB11611
|
| KEGG ID |
D10374
|
| MeSH ID |
C575157
|
| PubChem ID |
11965427
|
| TTD Drug ID |
D0Q9EV
|
| NDC Product Code |
65392-2803; 17337-0431; 59116-5170; 63592-3385; 66005-0049; 59651-445; 64552-4088; 64552-4089; 71796-011; 58159-054; 65129-1428; 69766-074; 66039-948; 0078-0911 |
| UNII |
038E5L962W
|
| Synonyms |
lifitegrast | L-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- | (2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid | Xiidra | SHP-606 | SHP606 | lifitegrast ophthalmic solution | SAR 1118 | SAR-1118 |
